Agenus Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Agenus Inc 公司

Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Agenus Inc簡介



公司代碼AGEN

公司名稱Agenus Inc

上市日期Feb 04, 2000

CEOArmen (Garo H)

員工數量316

證券類型Ordinary Share

年結日Feb 04

公司地址3 Forbes Rd

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02421-7305

電話17816744400

網址https://agenusbio.com/

公司代碼AGEN

上市日期Feb 04, 2000

CEOArmen (Garo H)

Agenus Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

39.00K

+23.66%

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+67.22%

Mr. Brian J. Corvese

Independent Director

4.60K

--

Wright (Timothy R)

Lead Independent Director

2.77K

--

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Jennifer S. Buell, Ph.D.

Director

--

Ms. Susan F. Hirsch

Independent Director

--

Dr. Steven O'Day, M.D.

Chief Medical Officer

--

Mr. Richard Goldberg

Chief Development Officer

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Thomas L. (Tom) Harrison, Ph.D.

Independent Director

39.00K

+23.66%

Ms. Christine M. Klaskin

Vice President - Finance

23.48K

+67.22%

Mr. Brian J. Corvese

Independent Director

4.60K

--

Wright (Timothy R)

Lead Independent Director

2.77K

--

Dr. Garo H. Armen, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Dr. Jennifer S. Buell, Ph.D.

Director

--

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Non-cash royalty revenue

108.59M

95.09%

Pre-commercial product revenue

4.24M

3.71%

Other services

1.04M

0.91%

Clinical product revenue

334.00K

0.29%

地區USD

名稱

營收

佔比

United States

113.16M

99.09%

Rest of World

1.04M

0.91%

業務

地區

業務USD

名稱

營收

佔比

Non-cash royalty revenue

108.59M

95.09%

Pre-commercial product revenue

4.24M

3.71%

Other services

1.04M

0.91%

Clinical product revenue

334.00K

0.29%

股東統計

更新時間: 5月13日週三

持股股東

股東類型

持股股東

佔比

Zydus Lifesciences Ltd

5.12%

Vanguard Capital Management, LLC

3.46%

Vanguard Portfolio Management, LLC

2.87%

Invus Public Equities Advisors, LLC

2.56%

Renaissance Technologies LLC

1.31%

其他

84.69%

持股股東

佔比

Zydus Lifesciences Ltd

5.12%

Vanguard Capital Management, LLC

3.46%

Vanguard Portfolio Management, LLC

2.87%

Invus Public Equities Advisors, LLC

2.56%

Renaissance Technologies LLC

1.31%

其他

84.69%

股東類型

持股股東

佔比

Investment Advisor

13.72%

Investment Advisor/Hedge Fund

5.42%

Hedge Fund

5.15%

Corporation

5.14%

Individual Investor

1.56%

Research Firm

1.12%

Pension Fund

0.91%

其他

66.99%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

275

10.91M

26.27%

-968.40K

2025Q4

304

9.95M

37.38%

--

2025Q3

332

9.95M

41.39%

+217.92K

2025Q2

334

9.73M

47.54%

+407.61K

2025Q1

334

9.33M

45.75%

-2.82M

2024Q4

341

8.45M

52.98%

-249.79K

2024Q3

351

8.70M

54.68%

-447.45K

2024Q2

347

9.21M

64.12%

-1.91M

2024Q1

356

10.69M

65.28%

-2.98M

2023Q4

374

11.90M

61.88%

+645.94K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Zydus Lifesciences Ltd

2.13M

5.56%

+2.13M

--

Jan 15, 2026

Invus Public Equities Advisors, LLC

1.06M

2.77%

--

Dec 31, 2025

Renaissance Technologies LLC

543.55K

1.42%

+477.35K

+721.07%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

485.30K

1.26%

+16.52K

+3.52%

Dec 31, 2025

Citadel Advisors LLC

423.24K

1.1%

+423.24K

--

Dec 31, 2025

Armen (Garo H.)

394.77K

1.03%

+8.98K

+2.33%

Mar 20, 2026

Geode Capital Management, L.L.C.

372.75K

0.97%

+25.76K

+7.42%

Dec 31, 2025

Wellington Management Company, LLP

290.65K

0.76%

--

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0%

iShares Russell 3000 ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

Fidelity Enhanced Small Cap ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

Schwab U.S. Small-Cap ETF

0%

SPDR Portfolio MSCI Global Stock Market ETF

0%

Global X Russell 2000 ETF

0%

Virtus LifeSci Biotech Clinical Trials ETF

0%

iShares Micro-Cap ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

Invesco NASDAQ Future Gen 200 ETF

佔比0%

Fidelity Enhanced Small Cap ETF

佔比0%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

Schwab U.S. Small-Cap ETF

佔比0%

SPDR Portfolio MSCI Global Stock Market ETF

佔比0%

Global X Russell 2000 ETF

佔比0%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

公告日期

除權除息日

類型

比率

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1

Feb 15, 2024

Merger

20→1